These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 34499866)

  • 1. Treatment of fibrotic interstitial lung disease: current approaches and future directions.
    Johannson KA; Chaudhuri N; Adegunsoye A; Wolters PJ
    Lancet; 2021 Oct; 398(10309):1450-1460. PubMed ID: 34499866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis and Management of Fibrotic Interstitial Lung Diseases.
    Collins BF; Luppi F
    Clin Chest Med; 2021 Jun; 42(2):321-335. PubMed ID: 34024407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
    Lamb YN
    Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases.
    Fischer A; Distler J
    Clin Rheumatol; 2019 Oct; 38(10):2673-2681. PubMed ID: 31423560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities.
    George PM; Spagnolo P; Kreuter M; Altinisik G; Bonifazi M; Martinez FJ; Molyneaux PL; Renzoni EA; Richeldi L; Tomassetti S; Valenzuela C; Vancheri C; Varone F; Cottin V; Costabel U;
    Lancet Respir Med; 2020 Sep; 8(9):925-934. PubMed ID: 32890499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating Genomics Into Management of Fibrotic Interstitial Lung Disease.
    Adegunsoye A; Vij R; Noth I
    Chest; 2019 May; 155(5):1026-1040. PubMed ID: 30660786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
    Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
    BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rheumatoid Arthritis (RA) associated interstitial lung disease (ILD).
    O'Dwyer DN; Armstrong ME; Cooke G; Dodd JD; Veale DJ; Donnelly SC
    Eur J Intern Med; 2013 Oct; 24(7):597-603. PubMed ID: 23916467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
    Makino S
    Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases.
    Holtze C; Flaherty K; Kreuter M; Luppi F; Moua T; Vancheri C; Scholand MB
    Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evolving pharmacotherapy of pulmonary fibrosis.
    Lota HK; Wells AU
    Expert Opin Pharmacother; 2013 Jan; 14(1):79-89. PubMed ID: 23265249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities.
    Spagnolo P; Ryerson CJ; Putman R; Oldham J; Salisbury M; Sverzellati N; Valenzuela C; Guler S; Jones S; Wijsenbeek M; Cottin V
    Lancet Respir Med; 2021 Sep; 9(9):1065-1076. PubMed ID: 34331867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progressive Fibrosing Interstitial Lung Diseases: Prevalence and Characterization in Two Italian Referral Centers.
    Faverio P; Piluso M; De Giacomi F; Della Zoppa M; Cassandro R; Harari S; Luppi F; Pesci A
    Respiration; 2020; 99(10):838-845. PubMed ID: 33264777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cohort study of Danish patients with interstitial lung diseases: burden, severity, treatment and survival.
    Hyldgaard C
    Dan Med J; 2015 Apr; 62(4):B5069. PubMed ID: 25872544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endotyping of progressive fibrotic interstitial lung diseases: It is the final destination that matters and not the journey.
    Tzouvelekis A; Bouros D
    EBioMedicine; 2020 Jan; 51():102591. PubMed ID: 31901856
    [No Abstract]   [Full Text] [Related]  

  • 16. Unclassifiable, or simply unclassified interstitial lung disease?
    O'Callaghan M; Bonella F; McCarthy C
    Curr Opin Pulm Med; 2021 Sep; 27(5):405-413. PubMed ID: 34172623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lung involvement in connective tissue diseases: a comprehensive review and a focus on rheumatoid arthritis.
    Marigliano B; Soriano A; Margiotta D; Vadacca M; Afeltra A
    Autoimmun Rev; 2013 Sep; 12(11):1076-84. PubMed ID: 23684699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease.
    Gibson CD; Kugler MC; Deshwal H; Munger JS; Condos R
    Lung; 2020 Aug; 198(4):597-608. PubMed ID: 32591895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
    Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The extended utility of antifibrotic therapy in progressive fibrosing interstitial lung disease.
    Sarkar P; Avram C; Chaudhuri N
    Expert Rev Respir Med; 2020 Oct; 14(10):1001-1008. PubMed ID: 32567402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.